Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Martin Glas, Florian Ringel et al.|Journal of Clinical Oncology|2016Cited by 197
Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.Ulrich Herrlinger, Martin Glas, Niklaus Schaefer et al.|Journal of Clinical Oncology|2013Cited by 29
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastomaNiklas Schäfer, Ulrich Herrlinger, Martin Proescholdt et al.|Neuro-Oncology|2017Cited by 21
Abstract 3416: Advancing cancer immunotherapy: PD-L1-targeted IFNa2a fusion protein RO7694744Moritz Rapp, Pablo Umaña, Harald Duerr et al.|Cancer Research|2025Cited by 0